Last updated: February 20, 2026
What is NDC 46122-0814?
NDC 46122-0814 identifies the drug Trelegy Ellipta, a combination inhaler used for maintenance treatment of airflow limitation in patients with chronic obstructive pulmonary disease (COPD) and asthma. The drug contains fluticasone furoate, umeclidinium, and vilanterol.
Market Overview
Market Size
The global COPD drugs market was valued at approximately $20 billion in 2022, with the inhaler segment accounting for a significant share. The U.S. market dominates, representing roughly 40-45% of global sales.
Key Competitors
Trelegy Ellipta competes with other combination inhalers such as:
- Spiriva Respimat (tiotropium bromide)
- Symbicort (budesonide/formoterol)
- Advair Diskus (fluticasone/salmeterol)
- Breo Ellipta (fluticasone furoate/vilanterol)
Market Penetration
Prescriptions for Trelegy Ellipta increased steadily post-approval (September 2017), driven by extensive labeling, multiple indications, and broader insurance coverage. U.S. prescriptions reached approx. 4 million annually as of 2022, indicating growth potential in underpenetrated markets.
Regulatory Environment
Trelegy Ellipta received FDA approvals for both COPD and asthma indications with emphasis on once-daily dosing, contributing to adherence. The patent expired in 2033, allowing for generic entry afterwards.
Revenue and Pricing Trends
Current Pricing
- Average Wholesale Price (AWP): Approximately $505 per inhaler.
- Average Selling Price (ASP): Estimated at $470.
- Patient Co-payment: Ranges from $25 to $50 depending on insurance plans.
Reimbursement Landscape
Major insurers cover Trelegy Ellipta extensively, but high copays impact patient access. Formularies favor this medication due to its approved multi-indication status and ease of use.
Recent Revenue Figures
- 2021: $2.8 billion (GSK reported)
- 2022: Estimated $3.2 billion, reflecting continued growth
Price Projections
Factors Influencing Future Pricing
- Patent expiration in 2033.
- Increased generic competition post-2033.
- Adoption rates in Europe and Asia-Pacific.
- Payer negotiations and formulary placements.
- Potential biosimilar/inhaler innovations.
Short-term (2023-2025)
Prices are expected to remain stable with slight reductions driven by negotiations and market expansion. Major payers may achieve discounts up to 15%, aligning ASP around $400-$420 per inhaler by 2025.
Mid-term (2026-2030)
As patent expiry approaches, biosimilar/inhaler generics could reduce market prices. Industry projections suggest a 20-30% price decline post-2033, with ASP declining to approximately $280-$330 per inhaler over the subsequent 5 years.
Long-term (Post-2033)
Generic competition is expected to significantly alter pricing dynamics. With multiple entrants, prices may fall by up to 60-70% compared to branded levels, reaching $150-$200 per inhaler.
Market Entry and Affordability Strategies
- Biosimilar Development: Companies developing inhaler biosimilars can target the post-patent period.
- Market Expansion: Focus on emerging markets with high COPD prevalence.
- Device Innovation: New inhaler technologies could sustain premium pricing.
- Reimbursement Negotiations: Payers favor drugs with proven adherence and efficacy profiles.
Key Takeaways
- Trelegy Ellipta captures a growing share of the COPD/asthma inhaler market, with stable pricing until patent expiration.
- Current U.S. ASP is around $470; stable through 2025.
- Price declines post-2033 are projected at 20-70%, driven by generics and biosimilars.
- Strategic focus on market expansion and device innovation remains critical.
- Payer negotiation strategies are crucial for maintaining revenue margins pre-expiration.
FAQs
Q1: What factors could accelerate generic market entry for Trelegy Ellipta?
A1: Patent expiration in 2033 is the primary factor. Regulatory approval pathways, patent litigation outcomes, and biosimilar development timelines influence entry speed.
Q2: How does pricing in international markets compare?
A2: Prices vary significantly, with regulatory and reimbursement policies affecting costs. Europe generally sees lower prices (~20-30% discount), while in emerging markets, prices are markedly lower to enhance access.
Q3: What are the main cost drivers for Trelegy Ellipta's price?
A3: Research and development expenses, manufacturing costs, and market exclusivity premiums primarily determine the current ASP.
Q4: How is insurance coverage influencing market penetration?
A4: Coverage enhances patient access; high copays hinder adoption. Insurers favor Trelegy for its efficacy, but negotiations aim to reduce patient cost-sharing.
Q5: What new developments could impact Trelegy Ellipta's market share?
A5: Introduction of more effective inhalers, fixed-dose combination therapies with novel mechanisms, and improved device technology could challenge its market dominance.
References
- GSK. (2022). Annual Financial Report.
- IQVIA. (2022). Prescribing Trends and Market Data.
- U.S. Food and Drug Administration. (2017). FDA Approvals for Trelegy Ellipta.
- EvaluatePharma. (2022). COPD Drugs Market Outlook.
- Centers for Disease Control and Prevention. (2021). COPD Prevalence and Impact.
